Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.

Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A.

Mult Scler. 2013 Nov;19(13):1765-72. doi: 10.1177/1352458513485981. Epub 2013 May 7.

PMID:
23652214
[PubMed - indexed for MEDLINE]
2.

Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b.

Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, Arnason BG.

Neurology. 1996 Dec;47(6):1463-8.

PMID:
8960728
[PubMed - indexed for MEDLINE]
3.

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.

Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group.

Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.

PMID:
19542262
[PubMed - indexed for MEDLINE]
4.

Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.

Lanzillo R, Prinster A, Scarano V, Liuzzi R, Coppola G, Florio C, Salvatore E, Schiavone V, Brunetti A, Muto M, Orefice G, Alfano B, Bonavita V, Brescia Morra V.

J Neurol Sci. 2006 Jun 15;245(1-2):141-5. Epub 2006 Apr 19.

PMID:
16626758
[PubMed - indexed for MEDLINE]
5.

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study.

Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group.

BMC Neurol. 2011 Oct 14;11:125. doi: 10.1186/1471-2377-11-125.

PMID:
21999142
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Effect of interferon-beta-1b on cognitive functions in multiple sclerosis.

Barak Y, Achiron A.

Eur Neurol. 2002;47(1):11-4.

PMID:
11803186
[PubMed - indexed for MEDLINE]
7.

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.

PMID:
19739877
[PubMed - indexed for MEDLINE]
Free Article
8.

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.

Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.

J Neurol Sci. 2004 Jul 15;222(1-2):13-9.

PMID:
15240190
[PubMed - indexed for MEDLINE]
9.

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC; 16-Year Long Term Follow-up Study Investigators.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):282-7. doi: 10.1136/jnnp-2011-301178. Epub 2011 Dec 21.

PMID:
22193561
[PubMed - indexed for MEDLINE]
10.

Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study.

Bergendal G, Fredrikson S, Almkvist O.

Eur Neurol. 2007;57(4):193-202. Epub 2007 Jan 1.

PMID:
17272938
[PubMed - indexed for MEDLINE]
11.

Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological, neuroradiological, and neurophysiological findings.

Piras MR, Magnano I, Canu ED, Paulus KS, Satta WM, Soddu A, Conti M, Achene A, Solinas G, Aiello I.

J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):878-85.

PMID:
12810771
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

[Current status of interferon beta-1b in multiple sclerosis therapy].

Hartung HP.

Med Klin (Munich). 2001 Sep 15;96 Suppl 1:11-6. German.

PMID:
11603110
[PubMed - indexed for MEDLINE]
13.

Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.

Flechter S, Vardi J, Finkelstein Y, Pollak L.

Isr Med Assoc J. 2007 Jun;9(6):457-9.

PMID:
17642394
[PubMed - indexed for MEDLINE]
Free Article
14.

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.

Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.

Mult Scler. 2009 Oct;15(10):1195-205. doi: 10.1177/1352458509106937. Epub 2009 Sep 29.

PMID:
19797261
[PubMed - indexed for MEDLINE]
15.

Neuropsychological performance and mood states following acute interferon-beta-1b administration in healthy males.

Exton MS, Baase J, Pithan V, Goebel MU, Limmroth V, Schedlowski M.

Neuropsychobiology. 2002;45(4):199-204.

PMID:
12097809
[PubMed - indexed for MEDLINE]
16.

Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

Hohol MJ, Guttmann CR, Orav J, Mackin GA, Kikinis R, Khoury SJ, Jolesz FA, Weiner HL.

Arch Neurol. 1997 Aug;54(8):1018-25.

PMID:
9267977
[PubMed - indexed for MEDLINE]
17.

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Poppe P, de Vos M, Lasri F, Bauer L, Dahms S, Wagner K, Pohl C, Sandbrink R.

Arch Neurol. 2007 Sep;64(9):1292-8.

PMID:
17846268
[PubMed - indexed for MEDLINE]
18.

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.

J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):773-80.

PMID:
11385012
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.

Minagar A, Ma W, Zhang X, Wang X, Zhang K, Alexander JS, Gonzalez-Toledo E, Albitar M.

Neurol Res. 2012 Jul;34(6):611-8. doi: 10.1179/1743132812Y.0000000055. Epub 2012 Jun 16.

PMID:
22709658
[PubMed - indexed for MEDLINE]
20.

The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.

Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB.

Arch Neurol. 1996 Feb;53(2):185-8.

PMID:
8639070
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk